Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy
Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder characterized by recurrent acute vaso-occlusive crises (VOCs and anemia). Gold standard treatments are hydroxycarbamide (HC) and/or different red blood cell (RBC) transfusion regimens to limit disease progression. Here...
Similar Items
-
Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide
by: Monika Blocka - Gumowska, et al.
Published: (2019-05-01) -
Spontaneous chest wall haematoma in chronic myeloid leukaemia
by: Mohamed Dwebi, et al.
Published: (2019-01-01) -
Management of the Sickle Cell Trait: An Opinion by Expert Panel Members
by: Valeria Maria Pinto, et al.
Published: (2023-05-01) -
A meta‐analysis of toxicities related to hydroxycarbamide dosing strategies
by: Joacy G. Mathias, et al.
Published: (2020-07-01) -
Drug therapy in patients with severe forms of sickle cell anemia: A nonrandomized clinical trial of combining l-carnitine with hydroxycarbamide therapy
by: Safaa A A. Khaled, et al.
Published: (2022-01-01)